Simple and sensitive liquid chromatography-tandem mass spectrometry methods for quantification of tadalafil in rat plasma: Application to pharmacokinetic study in rats

Archives of Pharmacal Research

Volumn 36, Issue 4, 2013, Pages 457-463

  Lee, Joo Hyun ^a   Oh, Ju Hee ^a   Lee, Young Joo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

LC MS MS; Pharmacokinetic study; Rat plasma; Tadalafil

Indexed keywords

ACEBUTOLOL; ACETONITRILE; FORMIC ACID; TADALAFIL; TERT BUTYL METHYL ETHER;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETONITRILES; ADMINISTRATION, ORAL; ANIMALS; CALIBRATION; CARBOLINES; CHROMATOGRAPHY, REVERSE-PHASE; DRUG STABILITY; FORMATES; LIMIT OF DETECTION; LIQUID-LIQUID EXTRACTION; MALE; METHYL ETHERS; PHOSPHODIESTERASE 5 INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84877876267     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0046-1     Document Type: Article

References (22)

1. Ali, I., and H.Y. Aboul-Enein. 2004. Validated method for tadalafil analysis in pharmaceutical preparations by capillary electrophoresis. Chromatographia 60: 187-191.
2. Bischoff, E. 2004. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. International Journal of Impotence Research 16(Suppl 1): S34-S37.
3. Cheng, C.L., and C.H. Chou. 2005. Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 822: 278-284.
4. Cleves, A.E., and A.N. Jain. 2008. Effects of inductive bias on computational evaluations of ligand-based modeling and on drug discovery. Journal of Computer-Aided Molecular Design 22: 147-159.
5. Forgue, S.T., B.E. Patterson, A.W. Bedding, C.D. Payne, D.L. Phillips, R.E. Wrishko, and M.I. Mitchell. 2006. Tadalafil pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology 61: 280-288.
6. Garraffo, R., T. Lavrut, S. Ferrando, J. Durant, N. Rouyrre, T.R. Macgregor, J.P. Sabo, and P. Dellamonica. 2011. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. Journal of Clinical Pharmacology 51: 1071-1078.
7. Hasegawa, K., O. Suzuki, K. Gonmori, I. Yamagishi, H. Nozawa, and K. Watanabe. 2012. Simultaneous analysis of sildenafil, vardenafil, tadalafil, and their desalkyl metabolites in human whole blood and urine by isotope dilution LC-MS-MS. Forensic Toxicology 30: 25-32.
8. Lee, J.H., J.H. Oh, and Y.J. Lee. 2011. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. Xenobiotica 41: 797-804.
9. Lue, T.F. 2000. Erectile dysfunction. New England Journal of Medicine 342: 1802-1813.
10. Man, C.N., N.M. Nor, R. Lajis, and G.L. Harn. 2009. Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column. Journal of Chromatography A 1216: 8426-8430.
11. Martin-Morales, A., J.M. Haro, A. Beardsworth, J. Bertsch, and S. Kontodimas. 2007. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). European Urology 51:541-50; discussion 550.
12. Murad, F. 1994. Cyclic GMP: synthesis, metabolism, and function. Introduction and some historical comments. Advances in Pharmacology 26: 1-5.
13. Nikolaou, P., I. Papoutsis, S. Athanaselis, G. Alevisopoulos, A. Khraiwesh, C. Pistos, and C. Spiliopoulou. 2011. Development and validation of a GC/MS method for the determination of tadalafil in whole blood. Journal of Pharmaceutical and Biomedical Analysis 56: 577-581.
14. Ramakrishna, N.V., K.N. Vishwottam, S. Puran, M. Koteshwara, S. Manoj, M. Santosh, J. Chidambara, S. Wishu, and B. Sumatha. 2004. Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 809: 243-249.
15. Ring, B.J., B.E. Patterson, M.I. Mitchell, M. Vandenbranden, J. Gillespie, A.W. Bedding, H. Jewell, C.D. Payne, S.T. Forgue, J. Eckstein, S.A. Wrighton, and D.L. Phillips. 2005. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clinical Pharmacology and Therapeutics 77: 63-75.
16. Rust, K.Y., H. Wilkens, R. Kaiser, D. Bregel, J. Wilske, and T. Kraemer. 2012. Detection and Validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS-application to forensic and therapeutic drug monitoring cases. Therapeutic Drug Monitoring 34: 729-735.
17. Seftel, A.D. 2004. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clinical Cardiology 27: I14-I19.
18. Shakya, A.K., A.N. Abu-Awwad, T.A. Arafat, and M. Melhim. 2007. Validated liquid chromatographic-ultraviolet method for the quantitation of tadalafil in human plasma using liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 852: 403-408.
19. Spence, R., A. Mandagere, B. Harrison, C. Dufton, and R. Boinpally. 2009. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. Journal of Pharmaceutical Sciences 98: 4962-4974.
20. Thompson, W.J. 1991. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacology & Therapeutics 51: 13-33.
21. Unceta, N., L. Echeazarra, M. Montana, J. Salles, A. Gomez-Caballero, M.A. Goicolea, and R.J. Barrio. 2012. Validation of an LC-ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samples. Journal of Pharmaceutical and Biomedical Analysis 70: 529-533.
22. Wrishko, R.E., J. Dingemanse, A. Yu, C. Darstein, D.L. Phillips, and M.I. Mitchell. 2008. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. Journal of Clinical Pharmacology 48: 610-618.